Bausch & Lomb is one of the largest vision care companies in the US. Bausch spun off from its former parent company, Bausch Health, in 2022 and it now operates in three segments: vision care, surgical ...

Eyecare company Bausch + Lomb (NYSE:BLCO) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year ...

With updated guidance reflecting stable long-term growth prospects, Bausch + Lomb is positioned to leverage its premium IOL pipeline and dry eye portfolio while navigating external pressures such ...

Bausch + Lomb Corp reported its Q1 2025 earnings, revealing a miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.07 against a forecast of $0.02 ...

Bausch + Lomb (BLCO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.07 per share a year ago. These figures are ...

(RTTNews) - Bausch + Lomb (BLCO) posted a first-quarter net loss attributable to Bausch + Lomb of $212 million, compared to a loss of $167 million, prior year. Loss per share was $0.60 compared to ...

Bausch & Lomb is now ranked among the top 10 undervalued stocks in the Healthcare sector on the Toronto Stock Exchange. A stock is considered undervalued if it trades at a discount to its ...

Gland Pharma Limited, a generic injectable & ophthalmic focused pharmaceutical company, has received approval from the USFDA ...

Eyecare company Bausch + Lomb (NYSE:BLCO) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year ...